FDMT Articles, 4D Molecular Therapeutics Inc. - From 02/07/24

4D Molecular Therapeutics Inc (NASDAQ:FDMT) shares are trading lower by 11.7% to $28.33 Wednesday afternoon after the company announced an upsized ...

Monday, 4D Molecular Therapeutics (NASDAQ:FDMT) released interim data from the Phase 2 PRISM clinical trial evaluating intravitreal 4D-15...

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 200 points on Monday. The Dow traded down 0.53% to 38,4...

Shares of Air Products and Chemicals, Inc. (NYSE: APD) fell sharply during Monday’s session after the company reported worse-than-expected fi...

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 points on Monday. The Dow traded down 1.04% to 38,...

4D Molecular Therapeutics (NASDAQ:FDMT) shares are trading higher after the company released interim data from the Phase 2 PRISM clinical tria...

U.S. stocks traded lower, with the Dow Jones falling over 300 points on Monday. Shares of The Estée Lauder Companies Inc. (NYSE: EL) rose s...

U.S. stocks traded lower this morning, with the Dow Jones index falling around 150 points on Monday. Following the market opening Monday, the Dow t...

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) rose sharply in today’s pre-market trading. 4DMT presented interim data from randomi...

Initial interim landmark data analysis (N=50 at 24 Weeks) will be presented by Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of th...